IVA - Inventiva Pharma Debt to Book Capitalization Ratio

The price history of Inventiva S.A. (IVA) on GURU.Markets reflects the dynamics of an asset whose production is based in French laboratories utilizing external contractors, with the current indicator standing at 1.15. Investors perceive Inventiva S.A. (IVA) as a high-risk venture project while awaiting test results. Successes in fibrosis therapy are achieved through close collaboration with global pharmaceutical behemoths.

inventivapharma.com - IVA Debts to Book Capitalization (period 07/04/2022 - 10/27/2026)

Metric breakdowns and analytics for Inventiva SA (IVA)

- price and consensus price forecast:

Price Chart Inventiva S.A.|IVA - Fair Value Consensus

- market capitalization data:

Market Value Inventiva Corp|IVA - Real Price to Acquire Entire Company

- book capitalization data:

Book Value per Share Inventiva|IVA - Book Capitalization|Market Cap to Net Assets Ratio inventivapharma.com|IVA - Aggregate Asset Value

- debt and liquidity data:

Debt to Equity Inventiva S.A.|IVA - Long-Term Debt to Equity|Short-Term Debt to Capital Inventiva Pharma|IVA - Company Total Debt Obligations|Debt to Book Value Inventiva Corp

Analysis of all company metrics:IVA (Inventiva S.A.)

Investors are assessing the resilience of Inventiva S.A. (IVA) through the ratio of total liabilities to market capitalization, which allows for a comparison of the current debt load against real-time market expectations. By analyzing the company's debt-to-book capitalization, it becomes evident how partner payments for liver fibrosis drugs are strengthening the balance sheet, reducing financial risks, and establishing a foundation for stable cash flow.

Competitors of Inventiva S.A.